In a recent article, Joshua Bauchner, a Partner and Chair of Mandelbaum Barrett PC’s Cannabis & Psychedelics Practice Group, emphasized the significance of the DEA’s recommendation to reschedule marijuana. Bauchner stated, “While it’s an important step forward in recognizing the long-established medicinal value of cannabis, the ultimate goal is not rescheduling, it’s descheduling.” This sentiment encapsulates the broader conversation surrounding cannabis reform.
The article discusses the DEA’s move to reclassify marijuana from Schedule I to Schedule III, a decision that could facilitate medical research and alleviate regulatory burdens on cannabis-related businesses. While hailed as a milestone by industry stakeholders, challenges remain, including discrepancies between federal and state laws and uncertainties regarding practical implications.
Bauchner’s commentary adds depth to the discourse, highlighting the imperative of comprehensive reform beyond reclassification. His perspective underscores the complexities involved in reshaping cannabis policy and the ongoing efforts to rectify historical injustices.
Read the full article here.